Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Novartis Pharmaceuticals49,001 enrolled

Overview

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

49,001

Conditions

Cardiovascular Disease and Lipoprotein(a)

Interventions

Blood draw for Lp(a)DIAGNOSTIC_TEST

Collect sample for Lipoprotein(a) testing

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Established CVD defined as one of the following: * History of a myocardial infarction (MI) ≥3 months and ≤10 years before the study visit * History of ischemic stroke ≥ 3 months and ≤ 10 years before the study visit * Symptomatic PAD (intermitted claudication with ankle-brachial index ≤0.90 and/or lower limb amputation or re-vascularization due to lower limb ischemia Exclusion Criteria: \- Patients currently enrolled in clinical studies with investigational drugs

Locations (900)

Outcomes

Primary Outcomes

Percentage of patients with normal and elevated Lipoprotein(a) (Lp(a)) levels in patients with established Cardiovascular Disease (CVD)

Prevalence of normal and elevated Lp(a) levels in patients with established CVD

Time frame: At screening

Secondary Outcomes

Lipoprotein(a) (Lp(a)) values

Evaluate the median and other relevant statistics describing the distribution of Lp(a) within the normal range and elevated Lp(a) levels

Time frame: At screening

Lp(a) values by region and country

Evaluate the median and other relevant statistics describing the distribution of Lp(a) by region and country

Time frame: At screening

Low-density lipoprotein cholesterol (LDL(C)) values (corrected and uncorrected)

Evaluate the median and other relevant statistics describing the distribution of LDL-C (corrected and uncorrected) within the normal range and with elevated Lp(a) levels

Time frame: At screening

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Andalusia, Alabama, United States

Novartis Investigative Site

Birmingham, Alabama, United States

Novartis Investigative Site

Huntsville, Alabama, United States

Novartis Investigative Site

Mobile, Alabama, United States

Novartis Investigative Site

Cottonwood, Arizona, United States

Novartis Investigative Site

Mesa, Arizona, United States

Novartis Investigative Site

Surprise, Arizona, United States

Novartis Investigative Site

Tucson, Arizona, United States

Novartis Investigative Site

Little Rock, Arkansas, United States

Novartis Investigative Site

Beverly Hills, California, United States

...and 890 more locations